XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.1
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($)
$ in Millions
Apr. 30, 2022
Jan. 31, 2022
Oct. 31, 2021
Apr. 30, 2021
Jan. 31, 2021
Oct. 31, 2020
Assets            
Short term investments (Equity securities with RDFV) $ 21   $ 91      
Liabilities            
Contingent Consideration 67 $ 92 89 $ 96 $ 0 $ 0
Fair Value, Measurements, Recurring            
Assets            
Total assets measured at fair value 692   1,084      
Liabilities            
Total liabilities measured at fair value 114   128      
Fair Value, Measurements, Recurring | Other Current Assets            
Assets            
Cash equivalents (money market funds) 571   919      
Derivative instruments (foreign exchange contracts) 38   9      
Short term investments (Equity securities with RDFV) 21   91      
Fair Value, Measurements, Recurring | Other assets            
Assets            
Trading securities 35   34      
Other investments 27   31      
Fair Value, Measurements, Recurring | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 12   5      
Contingent Consideration 64   62      
Fair Value, Measurements, Recurring | Other long-term liabilities            
Liabilities            
Deferred compensation liability 35   34      
Contingent Consideration 3   27      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)            
Assets            
Total assets measured at fair value 622   1,036      
Liabilities            
Total liabilities measured at fair value 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets            
Assets            
Cash equivalents (money market funds) 571   919      
Derivative instruments (foreign exchange contracts) 0   0      
Short term investments (Equity securities with RDFV) 16   83      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets            
Assets            
Trading securities 35   34      
Other investments 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 0   0      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities            
Liabilities            
Deferred compensation liability 0   0      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)            
Assets            
Total assets measured at fair value 70   48      
Liabilities            
Total liabilities measured at fair value 47   39      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets            
Assets            
Cash equivalents (money market funds) 0   0      
Derivative instruments (foreign exchange contracts) 38   9      
Short term investments (Equity securities with RDFV) 5   8      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets            
Assets            
Trading securities 0   0      
Other investments 27   31      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 12   5      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities            
Liabilities            
Deferred compensation liability 35   34      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)            
Assets            
Total assets measured at fair value 0   0      
Liabilities            
Total liabilities measured at fair value 67   89      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets            
Assets            
Cash equivalents (money market funds) 0   0      
Derivative instruments (foreign exchange contracts) 0   0      
Short term investments (Equity securities with RDFV) 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets            
Assets            
Trading securities 0   0      
Other investments 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.            
Liabilities            
Contingent Consideration 64   62      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities            
Liabilities            
Deferred compensation liability 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities | Resolution Bioscience, Inc.            
Liabilities            
Contingent Consideration $ 3   $ 27